152 terminated. 152 Phase 1, 63 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 152 | Terminated 152 |
| Phase 2 | 63 | Terminated 63 |
Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) AB-3028 - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Terminated | Arsenal Biosciences, Inc. | 3 | 2026-01-09 | 2026-11-16 |
| Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer Dapagliflozin - Prostate Cancer, Cancer of Prostate | Phase 1 | Terminated | Washington University School of Medicine | 5 | 2024-06-04 | 2026-06-30 |
| Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment Abemaciclib, Darolutamide, LHRH agonist/antagonist - Prostatic Neoplasms | Phase 1 | Terminated | Eli Lilly and Company | 10 | 2024-01-12 | 2026-06-26 |
| A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors VIO-01 - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Terminated | Valerio Therapeutics | 6 | 2024-01-10 | 2025-03-17 |
| Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors TNG348, Olaparib - Breast Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Tango Therapeutics, Inc. | 7 | 2023-12-08 | 2024-08-13 |
| A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. ONCT-534 - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Oncternal Therapeutics, Inc | 21 | 2023-09-20 | 2024-12-11 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Terminated | Evopoint Biosciences Inc. | 12 | 2023-09-20 | 2026-07-23 |
| Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate - Metastatic Prostate Cancer, Non-metastatic Prostate Cancer | Phase 1 | Terminated | Praful Ravi, MB BCHir, MRCP | 9 | 2023-08-09 | 2026-10-15 |
| Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer Abiraterone, Biospecimen Collection, Bone Scan - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 | Terminated | Emory University | 4 | 2023-08-03 | 2025-09-15 |
| 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) 64Cu-SAR-BBN, 67Cu-SAR-BBN - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Terminated | Clarity Pharmaceuticals Ltd | 4 | 2023-06-15 | 2025-08-29 |
| HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer HB-302/HB-301 Alternating 2-Vector Therapy - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Terminated | Hookipa Biotech GmbH | 12 | 2023-05-23 | 2024-06-12 |
| A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients Relugolix Pill, Ritonavir, Itraconazole - Prostate Cancer, Prostate Cancer Metastatic | Phase 1 | Terminated | University of Chicago | 60 | 2023-02-13 | 2024-09-19 |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors MDK-703, Checkpoint Inhibitor, Immune - Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Terminated | Medikine, Inc. | 26 | 2023-02-08 | 2024-05-08 |
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours [225]-FPI-2059, [111In]-FPI-2058 - Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck | Phase 1 | Terminated | 3B Pharmaceuticals GmbH | 19 | 2023-02-07 | 2025-08-24 |
| Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer ChAdOx1-PCAQ, MVA-PCAQ - Prostate Cancer | Phase 1 / Phase 2 | Terminated | Barinthus Biotherapeutics | 22 | 2023-01-30 | 2025-11-10 |
| Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log - Prostate Cancer, Prostate Adenocarcinoma | Phase 1 | Terminated | University of Chicago | 50 | 2023-01-24 | 2025-10-03 |
| A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) TmPSMA-02 - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Tceleron Therapeutics, Inc. | 1 | 2022-09-06 | 2023-08-18 |
| Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer Cirmtuzumab - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Terminated | University of California, San Diego | 6 | 2022-06-16 | 2024-10-09 |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868, Olaparib, Enzalutamide - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvation Bio Inc. | 82 | 2022-03-29 | 2025-11-06 |
| A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone - Prostatic Neoplasms | Phase 1 | Terminated | Janssen Research & Development, LLC | 3 | 2022-03-23 | 2025-02-03 |
Showing 20 of 152. Sign in to see all of them.
Breast Neoplasms (19) · Neoplasm Metastasis (13) · Ovarian Neoplasms (13) · Carcinoma, Non-Small-Cell Lung (9) · Neoplasms (9) · Pancreatic Neoplasms (8) · Lung Neoplasms (7) · Colorectal Neoplasms (5) · Stomach Neoplasms (5) · Urinary Bladder Neoplasms (5) · Carcinoma, Renal Cell (4) · Carcinoma, Transitional Cell (4) · Endometrial Neoplasms (4) · Genital Neoplasms, Male (4)
Genital Diseases (152) · Male Urogenital Diseases (152) · Urogenital Diseases (151) · Genital Diseases, Male (150) · Neoplasms by Site (149) · Urogenital Neoplasms (149) · Genital Neoplasms, Male (148) · Prostatic Diseases (148) · Neoplasms (143) · Female Urogenital Diseases (26) · Female Urogenital Diseases and Pregnancy Complications (26) · Breast Diseases (20) · Neoplasms by Histologic Type (20) · Skin Diseases (20) · Skin and Connective Tissue Diseases (20)
Docetaxel (19) · enzalutamide (13) · Prednisone (12) · abiraterone (8) · Abiraterone Acetate (7) · Magnetic Resonance Spectroscopy (7) · Cyclophosphamide (6) · Leuprolide (6) · bicalutamide (6) · olaparib (6) · Sirolimus (4) · darolutamide (4) · pembrolizumab (4) · Biopsy (3) · Goserelin (3)
National Cancer Institute (NCI) (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · Novartis Pharmaceuticals (4) · ESSA Pharmaceuticals (3) · Medical University of South Carolina (3) · NYU Langone Health (3) · OHSU Knight Cancer Institute (3) · Pfizer (3) · Rahul Aggarwal (3) · Roswell Park Cancer Institute (3) · University of Chicago (3) · University of Michigan Rogel Cancer Center (3) · Agennix (2) · Amgen (2) · AvenCell Europe GmbH (2)
United States (134) · Canada (11) · United Kingdom (10) · Spain (8) · Australia (7) · France (7) · Germany (6) · Belgium (4) · China (4) · Netherlands (4) · Austria (2) · Finland (2) · Italy (2) · Switzerland (2) · Taiwan (2)
Rahul Aggarwal, MD (3) · Christopher Logothetis (2) · Glenn Bubley, MD (2) · Robert B. Montgomery, MD (2) · Samuel Denmeade, MD (2) · William D Figg, Pharm.D. (2) · Aaron Enke (1) · Abhishek Solanki, MD (1) · Adam Crystal, MD, PhD (1) · Adam Dicker, MD (1) · Adam Dicker, MD, PhD (1)
PMID 20305636, PMID 20818327, PMID 22326922, PMID 25974235, PMID 31527168, PMID 32897402, PMID 33015525, PMID 33465252, PMID 33744986, PMID 34333820, PMID 35058326, PMID 35110415, PMID 36826464, PMID 36948505, PMID 37902861, PMID 38226958, PMID 38753757, PMID 38885312, PMID 39168098, PMID 39214047, PMID 39473059, PMID 39737899, PMID 39863139, PMID 39990653, PMID 40906325, PMID 41698328, PMID 42820295
2017 (4), 2019 (4), P30CA014089 (2), 2009 (1), 2014 (1), 2018 (1), 2023 (1), N01CM00039 (1), N01CM62202 (1), P30CA015704 (1), P30CA016056 (1), P30CA016672 (1), P30CA036727 (1), P30CA069533 (1), P30CA124435 (1)